Publications
Showing 121 to 130 of 540 Publications
| Title | Authors | Year | Journal |
|---|---|---|---|
| Regional differences in Alzheimer’s disease pathology confound behavioural rescue after amyloid-β attenuation | Morrone CD*, Bazzigaluppi P*, Beckett TL, Hill ME, Koletar MM, Stefanovic B**, McLaurin J** | 2019 | Brain |
| Regional brain atrophy and cognitive decline depend on definition of subjective cognitive decline | Morrison, C., Dadar, M.**, Shafiee, N., Villeneuve, S.*, Collins, L. D.* | 2021 | NeuroImage Clinical |
| Reentrant liquid condensate phase of proteins is stabilized by hydrophobic and non-ionic interactions | Krainer G, Welsh TJ, Joseph JA, Espinosa JR, Wittmann S, de Csilléry E, Sridhar A, Toprakcioglu Z, Gudiškytė G, Czekalska MA, Arter WE, Guillén-Boixet J, Franzmann TM, Qamar S, George-Hyslop PS*, Hyman AA, Collepardo-Guevara R, Alberti S, Knowles TPJ. | 2021 | Nature Communications |
| Reduced cerebrovascular reactivity and increased resting cerebral perfusion in rats exposed to a Cafeteria Diet | Gomez-Smith, M., Janik, R., Adams, C., Lake, E. M., Thomason, L. A. M., Jeffers, M. S., Stefanovic, B., & Corbett, D. | 2018 | Neuroscience |
| Recommendations of the 5th Canadian Consensus Conference on the diagnosis and treatment of dementia | Ismail Z*, Black SE*, Camicioli R*, Chertkow H*, Herrmann N*, Laforce R Jr.*, Montero-Odasso M*, Rockwood K*, Rosa-Neto P*, Seitz D*, Sivananthan S, Smith EE*, Soucy JP, Vedel I*, Gauthier S*, the CCCDTD5 participants | 2020 | Alzheimer's & Dementia |
| Recent advances from metabolomics and lipidomics application in alzheimer’s disease inspiring drug discovery. | Cuperlovic-Culf M, Badhwar A.** | 2019 | Expert Opin Drug Discov. |
| Rationale and design of the ENGAGE study : a double-blind randomized controlled preference trial using a comprehensive cohort design to measure the effect of a cognitive and leisure-based intervention in older adults with a memory complaint. | Belleville, S.**, Moussard, A.*, Ansaldo, A.I.**, Belchior, P.**, Bherer, L.**, Bier, N., Bohbot, V.D.**, Bruneau, M.A.**, Cuddy, L.L.**, Gilbert, B., Jokel, R.**, Mahalingam, K.*, McGilton, K.**, Murphy, K.J.**, Naglie, G.**, Rochon, E.**, Troyer, A.K.**, Anderson, N.D.**. | 2019 | Trials |
| Rasagiline, a monoamine oxidase B inhibitor, reduces in vivo [(18)F]THK5351 uptake in progressive supranuclear palsy | Ng KP, Therriault J, Kang MS, Struyfs H, Pascoal TA, Mathotaarachchi S, Shin M, Benedet AL, Massarweh G, Soucy JP, Rosa-Neto P*, Gauthier S* | 2019 | Neuroimage Clinical |
| Randomized placebo-controlled trial of nabilone for agitation in Alzheimer’s disease | Herrmann N, Ruthirakuhan M, Gallagher D, Verhoeff, NPLG, Kiss A, Black SE, Lanctôt K | 2019 | American Journal of Geriatric Psychiatry |
| Race- and Sex-Based Disparities in Alzheimer’s Disease Clinical Trial Enrollment in the United States and Canada: An Indigenous Perspective | Olson NL, Albensi BC* | 2020 | Journbal of Alzheimer's Disease Reports |
Showing 121 to 130 of 540 Publications